Navigation Links
Clinical studies show REMICADE reduces incidence of bowel surgeries in ulcerative colitis patients
Date:10/15/2007

PHILADELPHIA, PA, October 15, 2007- Clinical data presented today at the annual meeting of the American College of Gastroenterology (ACG) show that REMICADE significantly reduces the incidence of colectomy surgeries for patients with moderately to severely active ulcerative colitis (UC). According to a primary analysis of long-term extension data from the Active Ulcerative Colitis 1 and 2 trials (ACT trials), there is a 41 percent reduction in the incidence of colectomy, the surgical removal of the colon, in patients receiving REMICADE through 54 weeks, compared to those receiving placebo (p=0.015). REMICADE is the first and only biologic approved for the treatment of ulcerative colitis.

The analysis of the ACT extension trials included 728 patients from the initial ACT 1 and 2 trials, of whom 630 (86 percent) had complete follow-up through 54 weeks to ascertain whether they underwent colectomy surgery.

"These data illustrate that treatment with REMICADE significantly reduces the need for life-altering colectomy in patients with refractory ulcerative colitis," said Paul Rutgeerts, M.D., Ph.D., University Hospital Gasthuisberg, University of Leuven; Leuven, Belgium. "REMICADE may offer patients who fail other therapies the possibility of avoiding costly surgeries and hospitalizations while managing the symptoms of this debilitating disease long-term."

Separate data also presented at ACG today show the significant impact of colectomy on ulcerative colitis patients' use of healthcare services, including inpatient and outpatient hospital procedures, emergency room and physician visits, and laboratory and drug costs. A retrospective analysis of 411 patients, identified from the U.S. PharMetrics database as having UC and a colectomy between January 1, 2000, and June 30, 2005, found that total utilization of healthcare services increased significantly in the 12 months following colectomy, including inpatient and outpatient procedures (P
'/>"/>

Contact: Melissa Katz
215-325-6875
Centocor, Inc.
Source:Eurekalert

Page: 1 2 3 4 5 6

Related biology news :

1. Roche clinical trial registry and results database launched
2. NIAID begins clinical trial of West Nile virus vaccine
3. Compound might defeat African sleeping sickness, clinical trial beginning this month
4. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
5. Dalai Lama, top scientists to discuss science & clinical applications of meditation
6. Stem cells electric abilities might help their safe clinical use
7. Clinical trial to test stem cell approach for children with brain injury
8. New malaria vaccine shows promise in early clinical trial
9. Preclinical study of a new brain tumor therapy
10. Tramiprosate (Alzhemed? preclinical results published in Neurobiology of Aging
11. Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...lied mathematicians dissected the morphology of th...stic long leaf with a saddle-like arc midsection a...ple cause of the lily,s fan-like shapeelastic rela...growthwas revealed by using an equally simple tech... postdoctoral student at Harvard,s School of Engin...
(Date:11/23/2009)...ontrovertible evidence" that the volcanic super-er...00 years ago deforested much of central India, som...rt. , The volcano ejected an estimated 800 cubic...crater (now the world,s largest volcanic lake) tha...sh from the event has been found in India, the Ind...
(Date:11/23/2009)...microbiologist Louis Tisa has received two grants ...actinorhizal plants, widespread woody plants with ... soils. , The United States Department of Agric...ar, cellular and biomedical sciences, $399,000 to ...teria Frankia and Casuarina, an actinorhizal plant...
Breaking Biology News(10 mins):The cause behind the characteristic shape of a long leaf revealed 2Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2UNH prof. receives nearly $500,000 to research environmentally significant plants 2Fruit Even Healthier Than Thought 3A Study 56271 1Green Bridge Industries Inc to Exhibit ZAP 28TM 29 Stain Remover Pen at the L A County Fair 56267 1Green Bridge Industries Inc to Exhibit ZAP 28TM 29 Stain Remover Pen at the L A County Fair 56267 2New research strategy for understanding drug resistance in leukemia 56264 1New research strategy for understanding drug resistance in leukemia 56264 2New research strategy for understanding drug resistance in leukemia 56264 3
... The Senate Commission for the Investigation of H...e Forschungsgemeinschaft (DFG, German Research Fou...Values to the Federal Ministry for Labour and Soci...ute the set of recommendations for health protecti...ientific examination. 60 changes and additions to ...
... CHAMPAIGN, Ill. According to new research, old ...s on Earth, water also has been found in comets, o...ce. Now, scientists say this common fluid is not a...ow it, does not exist within our bodies," said Mar...or of Chemistry at the University of Illinois. "Wa...
... This press release is available in Spanish . ...ssue of the 1st of August the results of a detaile...rsity all through the last 50 million years. The s...f scientists from Australia, Spain, USA, UK, Holla...ve that the main concentrations of biodiversity ha...
Other Biology News:New and revised limits ensure safety in the workplace 2New and revised limits ensure safety in the workplace 3Water is 'designer fluid' that helps proteins change shape, scientists say 2Fossil and molecular evidence reveals the history of major marine biodiversity hotspots 2
(Date:11/24/2009)...FirstCall/--GenomicHealth,Inc.(Nasdaq: GHDX )today...airman,willpresentatthe21stAnnualPiperJaffrayHealt...09at10:00a.m.ET. ,, Toaccesstheliveandsubsequen...orRelationssectionofGenomicHealth,swebsiteat http:...bsiteatleast15minutespriortothebeginningoftheprese...
(Date:11/24/2009)...stomers with Partners Validated to Process and Ana..., Ottawa, ON (PRWEB) Novem...of products for biological sample collection, stab... global partner program. The program offers signif...nity and is designed to help partners scale and di...
(Date:11/24/2009)...-CellTherapeutics,Inc.(CTI)(NasdaqandMTA:CTIC)mana...CareConference.TheconferencewillbeheldDecember1-2,...onTuesday,December1at11:00a.m.EasternTimeinHolmes1...lbeavailableat www.celltherapeutics.com ,anditwill...ayHealthCareConference,NewYorkPalaceHotel,Holmes1(...
(Date:11/23/2009)...gami very high-tech origami. , Researchers at th...e for fabricating three-dimensional, single-crysta...ng photolithography and a self-folding process dri...a few microns thick, offer mechanical bendability ...me material. , "This is a completely different ap...
Breaking Biology Technology:Genomic Health to Present at Piper Jaffray Health Care Conference 2DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3Water droplets direct self-assembly process in thin-film materials 2
...ompany Receives Initial $3.7 Million Distribution ...rmaceutical Co., Ltd., CHENGDU, China, March 17 /...ical, Co., Inc., (OTC Bulletin Board: TYNP), a man...hinese medicine (,TCM,) based in,Chengdu, China, t...FDA,approval and is scheduled to launch Azithromyc...
...EW HAVEN, Conn., March 17 VION,PHARMACEUTICALS, I...sults for,the fourth quarter and year-end of 2007....n, or $5.05 per share,for the year ended December ...n, or $3.83 per share, for 2006. Weighted-average ...mber 31, 2007 and December 31, 2006,were 6.7 milli...
... Canadian Biotechnology Company advances pharmaceu...harmaceutical opportunities - ...wire-FirstCall/ - SemBioSys Genetics Inc.,(TSX:SBS...of therapeutic,proteins for metabolic and cardiova...nd financial results for the twelve-month period e...
Other Biology Technology:Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets 2Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets 3Vion Reports 2007 Fourth Quarter and Year-End Results 2Vion Reports 2007 Fourth Quarter and Year-End Results 3Vion Reports 2007 Fourth Quarter and Year-End Results 4SemBioSys announces 2007 financial and operational results 2SemBioSys announces 2007 financial and operational results 3SemBioSys announces 2007 financial and operational results 4SemBioSys announces 2007 financial and operational results 5SemBioSys announces 2007 financial and operational results 6SemBioSys announces 2007 financial and operational results 7SemBioSys announces 2007 financial and operational results 8SemBioSys announces 2007 financial and operational results 9SemBioSys announces 2007 financial and operational results 10SemBioSys announces 2007 financial and operational results 11SemBioSys announces 2007 financial and operational results 12SemBioSys announces 2007 financial and operational results 13
Corning Culture Flask, 150 cm2, Tc-Treated, Angled Neck, Vent Cap, Sterile from Sigma-Aldrich
Anti-YAP Polyclonal Antibody, Unconjugated from MBL International
...AP Stain for Mass Spectrometry Applications ,In t... emerged as a powerful protein identification and ... is now an important intermediate step in a set of...n of specific proteins in the proteome by mass fin...
...CR System is the only PCR system that ensures succ...ides accuracy, consistency, and dependability for ...he DNA templates. This system uses EPICENTRE's Fai...mostable enzymes that is capable of amplifying the...
Biology Products: